University of California
Berkeley, California, 94720, United States
NCT Number: NCT05861076
The study is a randomized acceptability trial involving the provision of three different doses of Moringa powder to be consumed daily by study participants.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Berkeley, California, 94720, United States
Moringa is a drought-resistant nutrient-dense tree with high concentrations of anti-inflammatory plant chemicals in its edible leaves and seeds. In preclinical studies Moringa has been shown to improve insulin resistance, dyslipidemia, and high blood pressure. But its effects in humans remain unclear. Moringa (20g leaf powder on two different days) supplementation decreased post-prandial glucose in Saharawi refugees with type 2 diabetes, compared to controls (Leone, et. al., 2018). In a randomized control trial in Spain, Moringa consumed as six daily capsules of dry leaf powder (2.4 g/day) for 12 weeks, significant decreased fasting blood glucose and glycated hemoglobin (HbA1c) among prediabetic subjects (Gomez-Martinez, et. al., 2021).
The investigators are conducting a testing trial of Moringa oleifera leaves, offered as powder, to be added to foods and/or drinks to test safety, acceptability and consumption of it in three different doses: 1 tsp, 2 tsp, and 3 tsp. Study participants will be randomly allocated to one of the three doses.
Among the studies that have been conducted with human subjects (individuals with diabetes), no adverse effects have been reported with whole leaf powder at up to a single dose of 50 g or using 8 g per day dose for 40 days (Stohs & Hartman, 2015).
The outcomes to be measured in this testing trial are the following:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
Time frame: 7 days
Total number of days that moringa powder was consumed
Time frame: 7 days
Total acceptability score, in a scale from 3 to 15 points, with higher scores indicating greater acceptance
Time frame: 7 days
Total number of side effects reported
Time frame: 7 days
Average number of teaspoons consumed (among days when consumption was reported)
Time frame: 7 days
Difference in skin carotenoid score from baseline to endline (score at endline minus score at baseline). Skin carotenoid levels are measured using the VeggieMeter. This measurement involves scanning a finger using a quick, non-invasive optical method that requires the participant to gently press a finger against a lens surface, with the help of a spring-loaded cover. Skin carotenoids are a biomarker for consumption of fruits and vegetables. A positive outcome value is expected as an indication of consumption of the Moringa powder.
Time frame: 7 days
Average taste score (possible scores range is 1-3, with higher scores indicating greater acceptance)
Time frame: 7 days
Average texture score (possible scores range is 1-3, with higher scores indicating greater acceptance)
Time frame: 7 days
Average visual appearance score (possible scores range is 1-3, with higher scores indicating greater acceptance)
Time frame: 7 days
Proportion who indicate willingness to continue consuming moringa powder
University of California, Berkeley
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05605834
Consumption, Toxicity
Cairo, Egypt
View Trial DetailsNCT05612516
Consumption
Cairo, Egypt
View Trial DetailsNCT05659823
Consumption, Nausea
Stavanger, Rogaland, Norway
View Trial DetailsNCT07721896
Anxiety Disorders, Behavior
Strasbourg, France
View Trial Details